Stockscreener 앱 받기
58.06
2.78%
-1.66
시장 영업 전:
58.21
0.15
+0.26%
전일 마감가:
$59.72
열려 있는:
$59.05
하루 거래량:
5.37M
Relative Volume:
0.88
시가총액:
$22.77B
수익:
$4.30B
순이익/손실:
$571.50M
주가수익비율:
40.64
EPS:
1.4285
순현금흐름:
$570.80M
1주 성능:
+5.56%
1개월 성능:
-12.31%
6개월 성능:
-32.89%
1년 성능:
-22.25%
1일 변동 폭
$57.92
$59.47
1주일 범위
$54.20
$60.85
52주 변동 폭
$54.11
$93.25
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
DXCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
58.06 | 23.29B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
130.59 | 224.77B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
102.69 | 155.63B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
362.22 | 142.80B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
95.87 | 123.31B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
86.30 | 49.97B | 5.88B | 1.34B | 799.60M | 2.3489 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
ROSEN, A LEADING NATIONAL FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, A LEADING NATIONAL FIRM, Encourages DexCom, Inc. - GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM - GlobeNewswire Inc.
Is DexCom Inc. (DC4) stock undervalued after correctionPortfolio Growth Summary & Capital Efficiency Focused Ideas - newser.com
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Will DexCom Inc. (DC4) stock keep high P E multiplesEarnings Trend Report & Capital Efficient Trade Techniques - newser.com
How Recent Developments Are Reshaping the DexCom Investment Story - Yahoo Finance
DexCom Inc. stock outlook for YEAR2025 Growth vs Value & AI Powered Market Entry Strategies - newser.com
Arcadia Investment Management Corp MI Acquires 5,365 Shares of DexCom, Inc. $DXCM - Defense World
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - Morningstar
Lost Money on DexCom, Inc. (DXCM)? Contact Levi & Korsinsky Before December 26, 2025 to Join Class Action - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. Investors With Losses to Contact the Firm - NewMediaWire
DEXCOM, INC. (NASDAQ: DXCM) INVESTOR ALERT Investors With - GlobeNewswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Aristotle Atlantic’s Core Equity Strategy Initiated a Position in Dexcom (DXCM) Backed by Its Robust Financial Stability - Insider Monkey
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. LawsuitDXCM - Morningstar
Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day - galvnews.com
Will DexCom Inc. stock continue dividend increasesJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Levi & Korsinsky Notifies DexCom, Inc. (DXCM) Shareholders of Class Action Lawsuit and December 26, 2025 Deadline - ACCESS Newswire
DexCom, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – DXCM - MarketScreener
Class Action Alert: Levi & Korsinsky Reminds DexCom, Inc. (DXCM) Investors of December 26, 2025 Deadline - Newsfile
ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. - GlobeNewswire
Frank Sands Reduces Stake in DexCom Inc by 50.4%, Impacting Portfolio by -1.25% - Yahoo Finance
Class Action Announcement for DexCom, Inc. Investors: A Securities Fraud Class Action Lawsuit With Expanded Class Period Was Filed Against CarMax, Inc.Contact Kessler Topaz Meltzer & Check, LLP - NewMediaWire
Legal and Regulatory Scrutiny Over Device Changes Might Change the Case for Investing in DexCom (DXCM) - Yahoo Finance
Is DexCom Inc. (DC4) stock cheap by valuation metricsWeekly Trend Report & Low Drawdown Momentum Ideas - newser.com
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Rothschild & Co Redburn Adjusts DexCom Price Target to $90 From $115, Maintains Buy Rating - MarketScreener
DexCom Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Allianz SE Has $4.54 Million Position in DexCom, Inc. $DXCM - Defense World
Winners And Losers Of Q3: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - Yahoo Finance
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - Morningstar
DCXM ALERT: Kirby McInerney LLP Reminds DexCom, Inc. Investors of Important Deadline in Class Action Lawsuit - The AI Journal
Dexcom: director Heller sells $58,766 in shares By Investing.com - Investing.com Nigeria
Dexcom: director Heller sells $58,766 in shares - Investing.com India
Levi & Korsinsky Helps Shareholders SueWallSt After DexCom, Inc. Stock Drops - ACCESS Newswire
Statistical indicators supporting DexCom Inc.’s strengthJuly 2025 Catalysts & Smart Allocation Stock Reports - newser.com
What analysts say about DexCom Inc stockAnalyst Upgrades & Superior Growth Investment - earlytimes.in
Morgan Stanley Lowers DexCom (NASDAQ:DXCM) Price Target to $63.00 - Defense World
Has DexCom Inc. found a price floorWeekly Trading Summary & Free Expert Approved Momentum Trade Ideas - newser.com
DexCom Stock Surge: A Chance to Profit? - StocksToTrade
DexCom Inc. stock outperforms competitors on strong trading day - MSN
DXCM Stockholders With Large Losses Should Contact Robbins LLP for Information About Leading the Dexcom, Inc. Securities Fraud Class Action - The Malaysian Reserve
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.01%
0.78%
자본화:
|
볼륨(24시간):